F S&P 500
5,209.25 -3.50 (-0.07%) F Dow Jones
39,191.00 -4.00 (-0.01%) F Nasdaq
18,161.25 -25.25 (-0.14%) E-mini Russell 2000 Index Futur
2,062.00 -2.80 (-0.14%) Petróleo
79.28 +0.29 (+0.37%) Oro
2,314.70 -7.60 (-0.33%)
Adial Pharmaceuticals, Inc. (ADIL)
Fuera de horario:
Adial Pharmaceuticals, Inc.
4870 Sadler Road
Suite 300
Glen Allen, VA 23060
United States
804 487 8196
https://www.adialpharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 4
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Cary John Claiborne MBA | CEO, President & Director | 728.31k | N/D | 1961 |
| Dr. Bankole A. Johnson DSc, FRCPsych, M.D., M.Phil, Ph.D. | Founder & Chief Medical Officer | 435k | N/D | 1960 |
| Mr. Joseph A. M. Truluck M.B.A., MBA | CFO, Treasurer & Secretary | 358.49k | N/D | 1978 |
| Mr. Tony Goodman | COO & Director | 33k | N/D | 1964 |
| Mr. John R. Martin J.D. | Chief Legal Officer | N/D | N/D | N/D |
| Ms. Catherine Fratila | Controller | N/D | N/D | N/D |
Descripción
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Gestión corporativa
La calificación ISS Governance QuickScore de Adial Pharmaceuticals, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
